Assessment of Serum Catestatin Level in Acne Vulgaris Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Isotretinoin: * Measure the serum levels of catestatin in patients with moderate and severe acne vulgaris versus healthy control persons. * Evaluate the effect of oral isotretinoin treatment on serum catestatin levels in patients with moderate and severe acne vulgaris.

Study summary

Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults.

Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.

Eligibility

Primary outcome measure(s)

• Evalaute serum level of Catestatin in acne patient — 12 weeks
  Assessment of clinical improvement according to:(8) G4(excellent:100% reduction) G3(good:75-99% reduction) G2(moderate: 50-74% reduction) G1(insufficient :1-49% reduction) G0(unchanged) G-1(worse)
• Evalaute the effect of treatment with systemic isotretinon — 12 weeks
  Evaluate the effect of treatment with systemic isotretinon therapy (0.5 mg/kg/day, up to 40 mg daily) on the level of serum Catestatin on the Participants whom suffering from Acne Vulgaris whether moderate or severe.

Trial sites (1)

More Aswan University trials in Egypt

Other trials for the same condition